/

Empresas

RI

No verificado

RIBOMIC Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaIr de comprasSalud

3 Comunicados de prensa

Ver todos los comunicados de prensa

07/10/2025

Salud

Ir de compras

Biotecnología

Infancia

Medicina - Varios

Farmacéutica

Industria

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

Fuente

Editor

1.00

0

05/11/2024

Industria

Salud

Ir de compras

Biotecnología

Infancia

Medicina - Varios

Farmacéutica

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort

Fuente

Editor

1.00

0

03/08/2024

Salud

Ir de compras

Biotecnología

Infancia

Medicina - Varios

Farmacéutica

Industria

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0